Literature DB >> 21963470

Evaluation of the immunogenicity and in vivo toxicity of the antimicrobial peptide P34.

Rodrigo de Almeida Vaucher1, Camila de Campos Velho Velho Gewehr, Ana Paula Folmer Correa, Voltaire Sant'Anna, Juliano Ferreira, Adriano Brandelli.   

Abstract

Immunogenicity and toxicity of antimicrobial peptide P34 were evaluated in vivo. BALB/c mice were inoculated intraperitoneally with peptide P34 alone and associated with Freund's adjuvant. For acute toxicity testing, different concentrations of the peptide P34 (82.5, 165.0, 247.5 and 330.0mg/kg) were orally administered. To evaluate the sub-chronic toxicity the tested dose of 0.825 mg/kg/day of the peptide P34 or nisin were administered for 21 days. There were no hypersensitivity reactions or significant increase in antibody titer during the immunogenicity experiment or death of animals during the acute or sub-chronic toxicity tests. The LD(50) was higher than 332.3 ± 0.76 mg/kg. No significant changes in serum biochemical parameters were observed in the animals treated with the peptide P34 unlike nisin-treated group showed a significant increase in alanine transaminase levels in comparison to controls. The group treated with 0.825 mg/kg/day of nisin showed histological changes in the spleen, skin and liver. In the group treated with peptide P34 histological changes in the spleen were observed, with the presence of megakaryocytes. Few studies report the use of animal models to evaluate the in vivo toxicity of antimicrobial peptides and such investigation is an essential step to ensure it safe use in foods.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963470     DOI: 10.1016/j.ijpharm.2011.09.020

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Inhibition of cell adhesion and immune responses in the mouse model of collagen-induced arthritis with a peptidomimetic that blocks CD2-CD58 interface interactions.

Authors:  Ameya S Gokhale; Rushikesh Sable; Jason D Walker; Leslie McLaughlin; Konstantin G Kousoulas; Seetharama D Jois
Journal:  Biopolymers       Date:  2015-11       Impact factor: 2.505

2.  In Vivo Assessment of Immunogenicity and Toxicity of the Bacteriocin TSU4 in BALB/c Mice.

Authors:  Tapasa Kumar Sahoo; Prasant Kumar Jena; Bhumika Prajapati; Laxita Gehlot; Amiya Kumar Patel; Sriram Seshadri
Journal:  Probiotics Antimicrob Proteins       Date:  2017-09       Impact factor: 4.609

3.  Safety of Lactobacillus plantarum ST8Sh and Its Bacteriocin.

Authors:  Svetoslav Dimitrov Todorov; Luana M Perin; Bruno M Carneiro; Paula Rahal; Wilhelm Holzapfel; Luís Augusto Nero
Journal:  Probiotics Antimicrob Proteins       Date:  2017-09       Impact factor: 4.609

4.  Immunosuppression by co-stimulatory molecules: inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice.

Authors:  Ameya Gokhale; Shanthi Kanthala; John Latendresse; Veena Taneja; Seetharama Satyanarayanajois
Journal:  Chem Biol Drug Des       Date:  2013-07       Impact factor: 2.817

5.  Purification and mass spectrometry based characterization of a pediocin produced by Pediococcus acidilactici 13.

Authors:  Evrim Güneş Altuntaş; Kamuran Ayhan; Selen Peker; Beycan Ayhan; Duygu Ozel Demiralp
Journal:  Mol Biol Rep       Date:  2014-07-12       Impact factor: 2.316

6.  Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model.

Authors:  Jayaram Lakshmaiah Narayana; Han-Ning Huang; Chang-Jer Wu; Jyh-Yih Chen
Journal:  Oncotarget       Date:  2015-05-30

7.  Assessment of anti-plasmodial activity of non-hemolytic, non-immunogenic, non-toxic antimicrobial peptides (AMPs LR14) produced by Lactobacillus plantarum LR/14.

Authors:  Ruchi Gupta; Vinoth Rajendran; Prahlad C Ghosh; Sheela Srivastava
Journal:  Drugs R D       Date:  2014-06

Review 8.  Use of Bacteriocins and Bacteriocinogenic Beneficial Organisms in Food Products: Benefits, Challenges, Concerns.

Authors:  Svetoslav Dimitrov Todorov; Igor Popov; Richard Weeks; Michael Leonidas Chikindas
Journal:  Foods       Date:  2022-10-10

9.  Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations.

Authors:  Samira Soltani; Riadh Hammami; Paul D Cotter; Sylvie Rebuffat; Laila Ben Said; Hélène Gaudreau; François Bédard; Eric Biron; Djamel Drider; Ismail Fliss
Journal:  FEMS Microbiol Rev       Date:  2021-01-08       Impact factor: 16.408

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.